title: Pathogenic lysosomal depletion in Parkinson's disease.
abstract: Mounting evidence suggests a role for autophagy dysregulation in Parkinson's disease (PD). The bulk degradation of cytoplasmic proteins (including α-synuclein) and organelles (such as mitochondria) is mediated by macroautophagy, which involves the sequestration of cytosolic components into autophagosomes (AP) and its delivery to lysosomes. Accumulation of AP occurs in postmortem brain samples from PD patients, which has been widely attributed to an induction of autophagy. However, the cause and pathogenic significance of these changes remain unknown. Here we found in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of PD that AP accumulation and dopaminergic cell death are preceded by a marked decrease in the amount of lysosomes within dopaminergic neurons. Lysosomal depletion was secondary to the abnormal permeabilization of lysosomal membranes induced by increased mitochondrial-derived reactive oxygen species. Lysosomal permeabilization resulted in a defective clearance and subsequent accumulation of undegraded AP and contributed directly to neurodegeneration by the ectopic release of lysosomal proteases into the cytosol. Lysosomal breakdown and AP accumulation also occurred in PD brain samples, where Lewy bodies were strongly immunoreactive for AP markers. Induction of lysosomal biogenesis by genetic or pharmacological activation of lysosomal transcription factor EB restored lysosomal levels, increased AP clearance and attenuated 1-methyl-4-phenylpyridinium-induced cell death. Similarly, the autophagy-enhancer compound rapamycin attenuated PD-related dopaminergic neurodegeneration, both in vitro and in vivo, by restoring lysosomal levels. Our results indicate that AP accumulation in PD results from defective lysosomal-mediated AP clearance secondary to lysosomal depletion. Restoration of lysosomal levels and function may thus represent a novel neuroprotective strategy in PD.
authors.affiliation: Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute-Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona 08035, Spain.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Dehay
authors.forename: Jordi
authors.initials: J
authors.lastname: Bové
authors.forename: Natalia
authors.initials: N
authors.lastname: Rodríguez-Muela
authors.forename: Celine
authors.initials: C
authors.lastname: Perier
authors.forename: Ariadna
authors.initials: A
authors.lastname: Recasens
authors.forename: Patricia
authors.initials: P
authors.lastname: Boya
authors.forename: Miquel
authors.initials: M
authors.lastname: Vila
mesh_terms: D000368:Aged; D000818:Animals; D000831:Animals, Newborn; D001343:Autophagy / Q000502:physiology*; D016923:Cell Death / Q000502:physiology; D045744:Cell Line, Tumor; D002463:Cell Membrane Permeability / Q000502:physiology; D002478:Cells, Cultured; D003600:Cytosol / Q000201:enzymology / Q000473:pathology; D004195:Disease Models, Animal; D004298:Dopamine / Q000502:physiology; D006801:Humans; D008247:Lysosomes / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure; D051379:Mice; D009474:Neurons / Q000378:metabolism / Q000473:pathology / Q000648:ultrastructure; D020734:Parkinsonian Disorders / Q000378:metabolism* / Q000473:pathology*; D010447:Peptide Hydrolases / Q000378:metabolism; D010588:Phagosomes / Q000378:metabolism / Q000473:pathology / Q000648:ultrastructure; D051381:Rats; D013378:Substantia Nigra / Q000378:metabolism / Q000473:pathology / Q000648:ultrastructure
chemical_list: D010447:Peptide Hydrolases; D004298:Dopamine